Gooch & Housego PLC (LSE:GHH), the Somerset-based photonics manufacturer whose crystals, optics and laser components sit inside defence systems, semiconductor tools and medical scanners, is about to leave the London market. On 26 August 2026 shareholders approved a recommended 1,230 pence per share cash offer from Greenlight Bidco, a vehicle of US Private Equity firm Arlington Capital Partners, valuing the equity at about £345.6 million. Completion is pencilled in for the fourth quarter of 2026.

That makes the case for a fresh look a specific one. The question is no longer whether G&H's record order book and surging defence sales will be rewarded by the market, but whether the deal closes on schedule, what could delay it, and what the price says about how overseas buyers value UK-quoted precision engineers.

Shareholders back a 40.7% premium bid, but one in five votes against

The offer was announced on 16 July 2026. Greenlight Bidco, indirectly owned by Arlington Capital Partners VII, L.P., agreed to pay 1,230 pence in cash per share, a 40.7% premium to the 874 pence close on 15 July 2026. Shareholders on the register on 19 June 2026 also keep the 4.9 pence interim dividend. The company put the Enterprise value at £400.5 million, or 25.9 times adjusted operating profit for the twelve months to 31 March 2026.

The board, led by chairman Gary Bullard, recommended the deal unanimously, citing "immediate and certain cash at a significant premium to recent levels" and arguing that private ownership would allow faster strategy execution than a UK-listed mid-cap could manage in consolidating markets. Peter Manos, managing partner at Arlington, said the firm was "excited to partner with Charlie Peppiatt, James Corte and the management team", and Bidco committed to keeping G&H's 11 Manufacturing sites across the UK, US and Asia.

The scheme document followed on 30 July 2026 and the votes on 26 August 2026. At the Court Meeting 79.17% of votes cast were in favour, clearing the 75% threshold; at the General Meeting 78.64% backed the special resolution. Both hurdles were passed, but around 21% of votes cast went against, a meaningful minority who evidently felt the price undervalued the business. The scheme now awaits UK National Security and Investment Act clearance, US Hart-Scott-Rodino approval and court sanction, all expected in the fourth quarter of 2026.

What Gooch & Housego does

G&H designs and manufactures precision optical components and photonic sub-systems: acousto-optic and electro-optic devices, crystals, fibre-optic modules and precision optics used to control, steer and measure laser light. It reports across three end markets. Aerospace & Defence supplies mission-critical optics for imaging, directed-energy weapons and space laser communications; Industrial sells components for high-power lasers and semiconductor tools; and Life Sciences provides optical assemblies and diagnostic instruments.

In the year to 30 September 2025 Industrial was the largest segment at £64.3 million of Revenue (42.8%), followed by Aerospace & Defence at £52.4 million (34.8%) and Life Sciences at £33.7 million (22.4%). The UK contributed 33.0% of sales, North America 32.5%, continental Europe 21.3% and Asia Pacific 13.2%. Acquisitions of Phoenix Optical (October 2024) and Global Photonics (June 2025) added capacity.

Half-year results: revenue up 15.5%, defence sales jump 52%

Interim results for the six months to 31 March 2026, published on 2 June 2026, showed revenue of £81.9 million, up 15.5% on £70.9 million a year earlier, with organic growth of 9.1%. Adjusted operating profit rose 16.9% to £7.2 million, nudging the Margin to 8.8% from 8.7%. Statutory profit before tax was £3.3 million (H1 2025: £2.9 million). Adjusted Earnings Per Share increased 9.3% to 16.4 pence, statutory EPS 13.6% to 9.2 pence, and the Interim Dividend was held at 4.9 pence.

Growth was overwhelmingly a defence story. Aerospace & Defence revenue climbed 51.7% to £35.6 million, while Industrial edged up 0.7% to £30.3 million and Life Sciences fell 7.7% to £16.0 million because of production disruption expected to ease in the second half. The order book reached a record £167.3 million, from £142.4 million at 30 September 2025. Cash from operations improved to £6.0 million from £3.6 million, but Capital Expenditure of £3.4 million pushed net Debt excluding leases to £36.6 million from £29.9 million at the September 2025 year-end (£49.8 million including leases).

For context, the year to 30 September 2025 delivered revenue of £150.5 million (up 10.7%), adjusted operating profit of £14.4 million (margin 9.6%), adjusted EPS of 35.4 pence and a 13.2 pence total dividend. Chief executive Charlie Peppiatt said the record order book "demonstrates the increased confidence our customers have in G&H", and the board left its FY2026 expectations unchanged.

What could move the shares before the deal completes

With the offer approved, the main near-term events are procedural. The two regulatory clearances, from the UK government under the National Security and Investment Act and from US antitrust authorities under Hart-Scott-Rodino, are the gating items. G&H's directed-energy and space communications work makes the UK national security review the more consequential, though the company expects the process to conclude in the fourth quarter. The court sanction hearing follows, after which shareholders are paid and the AIM Quotation is cancelled.

In previous years G&H has issued a full-year trading update in early October, which would give a final public read on whether defence-driven momentum carried through the second half. No competing bid has been announced, and directors' irrevocable undertakings, covering about 0.44% of the shares, remain binding even if a higher offer emerges.

Risks investors should watch

The principal risk is deal timing rather than deal failure. A prolonged national security review, or conditions attached to it, could push completion into 2027, while a refusal would be a far larger shock given the 874 pence undisturbed price.

On the underlying business, the half-year numbers highlight reliance on Aerospace & Defence, which now generates over 40% of revenue and almost all of the growth, while Industrial has been flat and Life Sciences is shrinking. Net debt excluding leases has risen from £16.0 million at September 2024 to £36.6 million at March 2026, with Leverage at 1.3 times adjusted EBITDA at the last year-end. Tariff-driven Supply constraints have forced the company to re-source raw materials and hold higher stock. A governance footnote: 53.9% of votes went against the remuneration report at the February 2026 AGM, prompting a further board statement on 10 August 2026.

Outlook

Barring a regulatory surprise, Gooch & Housego's run on AIM is likely to end before the year is out, with shareholders receiving 1,230 pence per share in cash. The outstanding questions are whether the UK and US clearances arrive on the expected timetable, whether court sanction follows promptly, and whether an October trading update confirms the record order book has translated into full-year delivery. More broadly, the 25.9 times operating profit multiple paid for a Business with sub-10% margins is a datapoint on how private capital is pricing defence-exposed photonics assets, though one transaction is not a sector-wide signal.